Midlands State University Library
Image from Google Jackets

Drug discovery in cancer epigenetics edited by Gerda Egger and Paola Arimondo

Contributor(s): Material type: TextTextSeries: Translational epigenetics seriesPublication details: Oxford : Elsevier, 2016Description: 475 pages : ill(chiefly color) 25 cmContent type:
  • text
Media type:
  • unmediated
Carrier type:
  • volume
ISBN:
  • 9780128022085
Subject(s):
Contents:
I. Introduction. Basic epigenetic mechanisms and phenomena -- Cancer epigenetics -- II. Methods and tools for epigenetic drug development -- Drug discovery methods -- Preclinical cancer models with the potential to predict clinical response -- Discovery of biomarkers for drug development -- Networks and consortia for epigenetic drug discovery -- III. Classes of epigenetic drugs -- DNA methyltransferase inhibitors -- Small molecule inhibitors of histone deacetylases and acetyltransferases as potential therapeutics in oncology -- Targeting histone methylation. The development of selective methyltransferase and demethylase inhibitors -- Bromodomains as anti-cancer targets -- Epigenetic readers interpreting the lysine methylome: biological roles and drug discovery -- Non coding RNAs: clinical and therapeutic applications -- IV. Clinical implications of epigenetic therapy. Clinical applications of epigenetic drugs -- Efficacy of combined epigenetic therapies -- Predicting and monitoring responses to epigenetic drugs -- Episensitization: a new word for a new concept -- The emerging potential for epigenetic therapeutics in non-cancer disorders
Reviews from LibraryThing.com:
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Call number Copy number Status Date due Barcode
Book Book Medical School Open Shelf RC268.4 DRU (Browse shelf(Opens below)) 150701 Available BK138374

Includes bibliographical references and index

I. Introduction. Basic epigenetic mechanisms and phenomena -- Cancer epigenetics -- II. Methods and tools for epigenetic drug development -- Drug discovery methods -- Preclinical cancer models with the potential to predict clinical response -- Discovery of biomarkers for drug development -- Networks and consortia for epigenetic drug discovery -- III. Classes of epigenetic drugs -- DNA methyltransferase inhibitors -- Small molecule inhibitors of histone deacetylases and acetyltransferases as potential therapeutics in oncology -- Targeting histone methylation. The development of selective methyltransferase and demethylase inhibitors -- Bromodomains as anti-cancer targets -- Epigenetic readers interpreting the lysine methylome: biological roles and drug discovery -- Non coding RNAs: clinical and therapeutic applications -- IV. Clinical implications of epigenetic therapy. Clinical applications of epigenetic drugs -- Efficacy of combined epigenetic therapies -- Predicting and monitoring responses to epigenetic drugs -- Episensitization: a new word for a new concept -- The emerging potential for epigenetic therapeutics in non-cancer disorders

There are no comments on this title.

to post a comment.